American Cancer Society. (2015, June 10). Breast Cancer. Retrieved from: http://www.cancer.org/cancer/breastcancer/index.
Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F, Barrios CH, et al. ESO-ESMO 2nd International Consesus Guidelines for advanced breast cancer (ABC2). (2014). The Breast. 23: 489-502.
Drugs and Health Products, Health Canada. (2018, May 7). Regulatory Decision Summary: Lynparza. Retrieved from: https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?linkID=RDS00399.
Health Canada. (2018, March 1). Regulatory Decision summary - Kisqali. Retrieved from: https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?linkID=RDS00352.
Morrow M, Burstein HJ, and Harris JR. Malignant tumors of the breast. DeVita VT Jr, Lawrence TS, & Rosenberg SA. (2015). Cancer: Principles and Practice of Oncology. (10th Edition). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 79: 1117-1156.
Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology clinical practice guideline. (2014, October). Journal of Clinical Oncology. 32(29): 3307-3331.
Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, Hicks DG, et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline. (2015, August). Journal of Clinical Oncology. 33(24): 2695-2706.
Zhu X, Verma S. Targeted therapy in HER2-positive metastatic breast cancer: a review of the literature. (2015, March). Current Oncology. 22(S1): S19-S28.×